Lv1
40 积分 2024-08-24 加入
Microbiota and immune-related adverse events in cancer immunotherapy
7天前
已完结
Impact of Checkpoint Inhibitor Immunotherapy Primarily Pembrolizumab on Infection Risk in Patients with Advanced Lung Cancer: A Comparative Retrospective Cohort Study
1个月前
已完结
Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
1个月前
已完结
Effect of hypercalcemia on immune system in patients with non-small cell lung cancer
2个月前
已完结
Spirometry at diagnosis and overall survival in non‐small cell lung cancer patients
2个月前
已完结
Emphysema Versus COPD in Patients Receiving Immune Checkpoint Inhibitors for NSCLC
3个月前
已完结
Emphysema Versus COPD in Patients Receiving Immune Checkpoint Inhibitors for NSCLC
3个月前
已完结
Chronic obstructive pulmonary disease as a double-edged sword—reshaping NSCLC immunotherapy paradigms
3个月前
已关闭
Integrating magnetic field-initiated thermal-thermodynamic therapy and immune checkpoint blockade to boost antitumor immunotherapy
3个月前
已关闭
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
4个月前
已完结
皖公网安备34019202002308
